Conference Coverage
Advertisement
Dr. Bekaii-Saab, of the Mayo Clinic, joins Dr. Nabhan to delve into the most groundbreaking studies unveiled at the meeting.
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.
The combination was shown to provide a 71% response rate, pointing to a new potential treatment for this patient population.
With an OS rate of about 80%, encorafenib and cetuximab with FOLFOX may serve as a new FDA-approved frontline regimen.
Encorafenib with cetuximab was approved by the FDA in 2024 for previously treated patients with BRAF V600E-mutant mCRC.
Dr. Kopetz elaborates on the key efficacy and safety findings, including how they compare to current standard treatments.
Dr. André elaborates on the efficacy and safety profiles of both treatments and their influence on current therapies.
Dr. Fakih elaborates on the combination's objective response rate, and how it can potentially redefine treatment paradigms.
Dr. Fakih elaborates on the Fc-enhanced design of botensilimab, and how the combination compares to prior therapies.
Dr. Peshin gives her thoughts on the future of GI oncology and the research that she found most interesting at ASCO GI 2025.
Dr. Strosberg focuses on how previous exposure to alkylating agents can influence tumor biology or immune response.
The study showed that favezelimab/pembrolizumab did not demonstrate a survival benefit over SOC.
Dr. Pasche discusses the trial that led to the TheraBionic P1 device's regulatory approval by the FDA.
Dr. Pant shared updates on a phase 1b dose escalation trial of gemcitabine, nab-paclitaxel, and lixumistat.
Dr. Pant offered insights on the key findings of zanidatamab's efficacy and safety in HER2-positive BTC.
Dr. Weinberg provided his perspective on the CheckMate 9DW expanded analyses, as well as multiple studies in CRC.
Dr. Shirakawa highlighted the results of the NAPOLEON-2 trial, including how RWD compare to clinical trial findings.
Dr. Dotan shared the effects of baseline geriatric and QOL assessments on outcomes for older patients with pancreatic cancer.
Dr. Abdelrahim details the impact of UGT1A1*28 polymorphism on tolerability in patients with mPDAC in the NAPOLI 3 study.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.